The Comparison With Clinical Impacts on Functional Capacity and Symptom Improvement According to the Rhythm Control in Patients With Heart Failure and Recent Onset Atrial Fibrillation

March 14, 2019 updated by: Yonsei University
Prospective randomized (rhythm control or rate control in heart failure patients with new onset atrial fibrillation) Objective of study 1. To analyze long term outcome of patients with heart failure with new onset atrial fibrillation according to the rhythm control 2. To analyze remodeling of atrium and ventricle by the new onset AF in heart failure patients 3. To analyze the change of LV function and functional capacity according to the rhythm in patients with HF and new onset AF

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Hui-Nam Pak, MD
  • Phone Number: +82-2-2228-8459
  • Email: hnpak@yuhs.ac

Study Locations

  • Korea, Republic of
      • Seoul, Korea, Republic of, 120-752
        • Recruiting
        • Severance Cardiovascular Hospital, Yonsei University College of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients with Heart failure and Atrial fibrillation within 1year (20~80 years old)
  2. LA diameter < 5mm
  3. LVEF 20~49%
  4. patients possible to anticoagulation and anti arrhythmic drug
  5. Expected survival >1yr

Exclusion Criteria:

  1. Impossible to anticoagulation or anti arrhythmic drug
  2. valvular atrial fibrillation ( Mitral valve stenosis, Mitral valve plasty, valve replacement)
  3. LV ejection fraction < 20%
  4. Structural cardiac disease
  5. Catheter ablation history for AF, maze surgery
  6. patient with severe medical disease
  7. Impossible to anticoagulation or anti arrhythmic drug

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Sinus Rhythm Control group
  1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation
  2. Cardioversion after 1 month
  3. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)
  4. If AF recur, RFCA
Procedure: Sinus Rhythm control
Active Comparator: Pulse Rate Control Group
  1. No AAD, just anticoagulation
  2. HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)
  3. Without the treatment about antiarrhythmia and rhythm control, diffraction of rate control, the subject will be drop out for study.
Procedure: Pulse Rate control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
improvement of left ventricular function according to the rhythm control in patient with heart failure and new onset atrial fibrillation
Time Frame: 1 year
ejection fraction change (echocardiography)
1 year
functional capacity according to the rhythm control in patient with heart failure and new onset atrial fibrillation
Time Frame: 1 year
peak VO2 (cardio pulmonary test ; CPX)
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
remodeling of atrium by the new onset AF in heart failure patients The change of LV function and functional capacity according to the rhythm in patients with HF and new onset AF
Time Frame: 1 years late
Echo cardiography (LV ejection fraction, LV wall thickness, LV mass index, LA dimension, LA appendage velocity, E/E'), EKG, 24 hours Holter recording
1 years late
remodeling of ventricle by the new onset AF in heart failure patients The change of LV function and functional capacity according to the rhythm in patients with HF and new onset AF
Time Frame: 1 years late
Echo cardiography (LV ejection fraction, LV wall thickness, LV mass index, LA dimension, LA appendage velocity, E/E'), EKG, 24 hours Holter recording
1 years late

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yonsei University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2014

Primary Completion (Anticipated)

November 1, 2019

Study Completion (Anticipated)

November 1, 2019

Study Registration Dates

First Submitted

November 20, 2014

First Submitted That Met QC Criteria

December 19, 2014

First Posted (Estimate)

December 22, 2014

Study Record Updates

Last Update Posted (Actual)

March 18, 2019

Last Update Submitted That Met QC Criteria

March 14, 2019

Last Verified

March 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 4-2014-0811

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on Sinus Rhythm control

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe